BioMedWire
Media & Internet · California, United States · 1-10 Employees
View Company Info for Free
Overview
Headquarters
1728 Ocean Ave PMB BMW, San Francisco, C...Phone Number
(415) 949-5050Website
www.biomedwire.comRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Jan
Feb
Mar
Apr
May
Jun
ZI Rank
1
1
1
1
1
1
About BioMedWire
BioMedWire (BMW) is a diversified financial news and publishing company that specializes in the medical and biotechnology sectors. The company offers a range of services including brand awareness, corporate communications, press release enhancement, and social media solutions, aimed at helping public companies, start-ups, and private firms enhance their market visibility. With an extensive network of over 5,000 distribution outlets, BioMedWire maximizes exposure for its clients to a diverse audience of journalists, investors, and market participants. As a technology-driven communications platform, BMW aggregates and distributes news on emerging market opportunities in life sciences, pharmaceuticals, and related fields.Explore more
BioMedWire Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is BioMedWire your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Click to see if BioMedWire had a recent Job posting/layoffs
Funding: Get notified immidiatlly once BioMedWire has new funding data
Website visits: Recent activity has been detected on your website
Congratulate Masked Content for being promoted to Masked Content at BioMedWire
Check if BioMedWire has recently received funding, and reach out quickly before it becomes old news!
Earning: See what the market has to say on BioMedWire recently announced quarterly report
Check out if BioMedWire is spiking on competitors!
Product Launch: Get notified when BioMedWire launches new products
Competitive Alert! Recent activity has been detected by your competitor Masked Content
BioMedWire, which may be a good buyer, showed buying intent in Masked Content Topic
Recommended Actions
Reach out to Masked Content who joined BioMedWire as Masked Content
Find more new buyers
Compare Similar Companies to BioMedWire
Compare insights from companies similar to BioMedWire, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
BioMedWire is experiencing very low activity levels compared to other companies in the Media & Internet sector.
What does this means?
BioMedWire is drawing exceptional interest within the Media & Internet industry, suggesting notable developments or strong market momentum, learn more about BioMedWire.
BioMedWire Tech Stack
A closer look at the technologies used by BioMedWire
See more technologies
BioMedWire News & Media
Quantum BioPharma Ltd. (NASDAQ: QNTM) Advancing Innovative, First-in-Class, Patented MS Therapy
NEW YORK, June 25, 2026 (GLOBE NEWSWIRE) -- via BioMedWire — Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) today announces its placement in an editorial published by BioMedWire (BMW), one of 75+ brands within the Dynamic Brand Portfolio@IBN (InvestorBrandNetwork), a specialized communications platform with a focus on financial news and content distribution for private and public companies and the investment community.Next-Generation DNA Repair Inhibitors Could Capture Billions in Emerging Market
AUSTIN, Texas, June 24, 2026 (GLOBE NEWSWIRE) -- BioMedWire Editorial Coverage: Oncology research is moving through one of its most active stretches in years. DNA Damage Response (“DDR”) inhibitors, a category of drugs that work by blocking cancer cells' capacity to fix their own damaged DNA, are growing well beyond the poly ADP ribose polymerase (“PARP”) inhibitor that first defined the category. DDR-inhibiting therapies generated an estimated $7 billion-plus in worldwide sales in 2025, and theThe Quest to Repair What Multiple Sclerosis Takes Away
AUSTIN, Texas, June 24, 2026 (GLOBE NEWSWIRE) -- BioMedWire Editorial Coverage: Multiple sclerosis (“MS”) gradually strips people of command over their own bodies, advancing steadily with no available cure. More than 2.9 million people across the globe are currently living with the disease. But even with generations of scientific study and research, every approved treatment still falls short of one essential objective: bringing the disease to a complete stop. Existing therapies can slow its advaQuantum BioPharma Ltd. (NASDAQ: QNTM) Developing Patented, First-in-Class MS Treatment That Offers Different Approach
NEW YORK, June 23, 2026 (GLOBE NEWSWIRE) -- via BioMedWire — Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) today announces its placement in an editorial published by BioMedWire (BMW), one of 75+ brands within the Dynamic Brand Portfolio@IBN (InvestorBrandNetwork), a specialized communications platform with a focus on financial news and content distribution for private and public companies and the investment community.
Read more news
Top Media & Internet Companies
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding BioMedWire
Sign Up For FreeTo access detailed company insights
BioMedWire (BMW) is a diversified financial news and publishing company that specializes in the medical and biotechnology sectors. The company offers a range of services including brand awareness, corporate communications, press release enhancement, and social media solutions, aimed at helping public companies, start-ups, and private firms enhance... Read More
